PATENT CLAIM ANALYSIS

Application Number: 16144916
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "094000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 16):
The method of  claim 4 , wherein orally administering the dosage form containing the disodium salt form of zoledronic acid results in a 24-hour sustained plasma level factor in the human being that is at least about 2 times that of 4 mg of zoledronic acid administered intravenously.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16002888', '15934785', '15952017', '15989641', '15432777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8597154361618728
- 35 USC 102 Novelty (BERT): 0.6787728420111047
- Combined Prediction Score: 0.841621176746796
- Mean Citation Score: 612.5456360000002
- Max Citation Score: 617.901
- Similarity Product: 488.3305558279752

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test